Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Filings indexed 336 across all filing types
Latest filing 2023-03-27 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the exercise price for outstanding warrants (Shinju-insugwon-haengsa-gaek) due to market price fluctuations and corporate actions (bonus issue). This type of filing is a standard disclosure for companies with convertible securities or warrants, categorized under 'Capital/Financing Update' (CAP) as it directly relates to the company's capital structure and potential dilution.
2023-03-27 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Samil Pharmaceutical regarding the adjustment of the conversion price for convertible bonds due to market price fluctuations (specifically following a bonus issue). This type of disclosure, which details changes to the terms of financial instruments like convertible bonds, falls under capital structure updates. Since it specifically addresses the adjustment of conversion prices for existing debt instruments, it is classified as a Capital/Financing Update.
2023-03-27 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the exchange price for convertible bonds (exchangeable bonds) due to market price fluctuations and corporate actions like bonus issues. This falls under capital structure changes and financing adjustments. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most appropriate category for adjustments to conversion or exchange prices of debt instruments.
2023-03-27 Korean
[기재정정]전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Samil Pharmaceutical regarding the adjustment of conversion prices for convertible bonds due to a bonus issue (free capital increase). This type of disclosure, which details changes to the capital structure and financial instruments (conversion price adjustments), falls under the category of capital and financing updates. It is not a general regulatory announcement (RNS) because it is a specific, substantive financial event disclosure.
2023-03-27 Korean
[기재정정]전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Samil Pharmaceutical regarding the adjustment of the conversion price for convertible bonds due to a bonus issue (free capital increase). This type of disclosure, which details changes to the terms of financial instruments like convertible bonds, falls under capital structure and financing updates. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most appropriate category for adjustments to conversion prices of debt instruments.
2023-03-27 Korean
[기재정정]전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the adjustment of the exercise price for warrants (신주인수권행사가액의 조정) due to a bonus issue (무상증자). This type of filing, which details changes to the capital structure and conversion/exercise prices of financial instruments, falls under the 'Capital/Financing Update' category as it directly relates to the company's financing activities and capital structure adjustments.
2023-03-27 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.